CervoMed (CRVO) Financials

CervoMed’s latest quarter shows a company with a strong cash position, but still very much in cash-burn mode. In Q1 2026, CervoMed reported no revenue, an operating loss of about $8.1 million, and a net loss of about $8.0 million. The good news is that the balance sheet remains solid enough for now, with roughly $12.9 million in cash and short-term investments at quarter-end and only $4.5 million in current liabilities.

What stands out most is the sharp drop in cash compared with a year ago. Cash and short-term investments fell from about $35.3 million in Q1 2025 to about $12.9 million in Q1 2026. That decline reflects continued operating losses and a company that is still funding research and development ahead of commercialization.

• Cash and short-term investments totaled about $12.9 million at the end of Q1 2026, giving the company near-term liquidity.
• Current liabilities were only $4.5 million, which keeps the near-term balance sheet relatively manageable.
• Interest and investment income of about $147,000 helped offset a small portion of operating losses.
• Operating cash burn improved slightly year over year, with operating cash outflow narrowing from about $8.1 million in Q4 2025 to about $8.0 million in Q1 2026.
• The company still has no revenue in Q1 2026, so progress depends on future clinical or commercial milestones rather than current sales.
• Research and development expense was still elevated at about $5.1 million, showing continued investment in the pipeline.
• Selling, general and administrative expense was about $3.0 million, a meaningful but smaller part of the quarterly burn.
• The company’s equity remains positive at about $10.6 million, but retained earnings are deeply negative at roughly $(105.7) million, reflecting cumulative losses.
• Revenue dropped to $0 in Q1 2026 from $8,726 in Q4 2025 and much higher levels in prior quarters, indicating no meaningful recurring sales base yet.
• The company posted a quarterly net loss of about $8.0 million, extending a long run of losses and ongoing cash consumption.

Looking at the broader trend, CervoMed’s business has been inconsistent and highly dependent on financing and investment activity. In 2024 and 2025, quarterly revenue was volatile, ranging from roughly $1.5 million to $3.3 million in some periods, but it has now fallen back to zero in the latest quarter. At the same time, operating expenses have remained in the $7 million to $9 million range per quarter, which is difficult to support without meaningful revenue growth or additional capital.

Investor takeaway: CervoMed still has enough liquidity to operate in the near term, but the combination of no revenue, persistent losses, and a materially reduced cash balance suggests continued financing risk. Until the company shows durable revenue growth or a clear path to reducing its burn rate, the stock will likely remain highly speculative.